常用名 | LJI308 | CAS号 | 1627709-94-7 |
---|---|---|---|
价格 | ¥需询单/1kg ¥需询单/1g ¥需询单/1mg | 纯度 | 98.0% |
备货期 | 需询单 | 库存 | 询单 |
产品详情(用途,包装等)
用途: LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.IC50 value: 6/4/13 nMTarget: RSK1/2/3in vitro: LJI308 efficiently inhibits RSK activity. LJI308 inhibites S6K1 with an IC50 of 0.8 μM, representing a 200-fold lower inhibition than that of RSK2. LJI308 inhibits MEK4 less than 50% at 10 μMand HIP kinase 1 less than 50% at 1 μM. [1] LJI308 inhibits the growth and survival of TNBC. LJI308 also suppresses the growth of HTRY-LT cells in 3-dimensional soft agar cultures. LJI308 is one of the first potent and effective targeted therapies for TNBC that, unlike currently utilized drugs, exhibits efficacy in eliminating the CSC population. [2] 物理化学性质: CAS号:1627709-94-7 常用中文名:LJI308 常用英文名:LJI308 分子式:C21H18F2N2O2 分子量:368.377 密度:1.3±0.1 g/cm3 沸点:486.6±45.0 °C at 760 mmHg 熔点:N/A 闪点:248.1±28.7 °C 储存条件:-20℃ |